CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Ian Mortimer

President and Chief Executive Officer, Xenon

Search every verified Ian Mortimer interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Ian Mortimer, President and CEO of Xenon Pharmaceuticals, discussed the company's recent progress in a September 2026 conference call, including the submission of a new drug application (NDA) to the U.S. FDA for azetukalner (AZK) as a treatment for focal seizures. He described the NDA submission as a significant step toward becoming a fully integrated neuroscience company, citing positive data from two pivotal trials. Mortimer also addressed a voluntary pause in enrollment for new patients in studies for major depressive disorder and bipolar depression, stating it was a precautionary measure taken in consultation with the data safety monitoring board following an analysis of neuropsychiatric adverse events, and that it was expected to be temporary. In a separate appearance, Mortimer was recognized as the winner of the 2026 Bloom Burton Award for his leadership in Canadian biotech. He reflected on Xenon's growth over his five years as CEO, noting the company expanded to about 400 employees and increased its market capitalization roughly tenfold. He highlighted the phase 3 results for azetukalner in epilepsy, describing them as exceeding expectations and showing the best placebo-adjusted efficacy seen in the most common form of epilepsy. Mortimer also mentioned that the company had raised approximately $2 billion over the past five years, including about $1 billion in the last year, which he attributed to strong clinical results attracting investor interest.

Recent appearances

  • 2026 Bloom Burton Award Winner - Ian Mortimer of Xenon Pharmaceuticals

    September 25, 2026 · 📺 Bloom Burton & Co.

    Ian Mortimer, the winner of the 2026 Bloom Burton Award, is celebrated for his exceptional leadership in Canadian biotech. As President and CEO of Xenon Pharmaceuticals, Ian led the company through an unprecedented period of performance, including positive phase 3 clinical trial results with Xenon’s novel epilepsy treatment azetukalner (AZK) in adults with focal onset seizures, the expansion of its phase 3 clinical program for patients with major depressive disorder and bipolar depression, and the preparation of a submission of a new drug application with the U.S. FDA. Xenon also executed a…

    Watch on YouTube ↗

  • Xenon Pharmaceuticals Details Azetukalner NDA Submission for Focal Seizures and Psychiatry Program

    September 21, 2026 · 📺 i101

    Xenon Pharmaceuticals Details Azetukalner NDA Submission for Focal Seizures and Psychiatry Program Update | Sep 17, 2026. Twitter - https://x.com/i101yt If you find our work useful, please support us by purchasing a Super Thanks— it truly helps us a lot. #earningscall #StockMarketNews #conferenceCall Earnings Call | Earnings Conference Call | Earnings concall | concall | quarterly results | Stock News | Full Year results | Fiscal Year results | investment news | stock latest news | Annual Meeting of Shareholders | Annual Meeting of Unitholders | Special and Annual Meeting of Shareholders…

    Watch on YouTube ↗

  • 2023 Bloom Burton Award Finalist - Ian Mortimer of Xenon Pharmaceuticals

    October 06, 2023 · 📺 Bloom Burton & Co.

    Ian Mortimer is a 2023 Bloom Burton Award finalist with a impressive tenure at Xenon Pharmaceuticals. Ian currently leads one of the most exciting biotechnology companies in Canada with a strong neurology pipeline and a lead candidate in phase 3 clinical trials. The Bloom Burton Award honours an individual scientist, inventor, executive, entrepreneur, industry leader, or policy maker who made the greatest contribution to Canada’s innovative healthcare industry in the previous year. Nominees are accepted from any of the biotechnology, pharmaceutical, medical device, diagnostic/imaging, researc…

    Watch on YouTube ↗

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →